Company overview: NanoHybrids fills an unmet market need for molecularly sensitive contrast agents. Specifically, agents produced by the company enable a new imaging tool, photoacoustic imaging, to non-invasively detect cancer, leading to highly advanced and personalized treatment strategies. The company’s proprietary knowledge in contrast agent design makes them uniquely qualified to introduce these agents for sale to preclinical researchers, in diagnostic assays, and finally in the clinic.
How TVL helped: The TVL deal team conducted market validation and research into the FDA approval process in the company’s three intended markets: preclinical, in-vitro diagnostic, and clinical. Additionally, the TVL students developed a detailed and dynamic financial model for the company to use in projecting revenue, expenses, and likely valuations based on variables the company can manipulate. Lastly, the TVL team worked closely with the company to develop a business plan based on their findings which will aid the company as it seeks to raise venture capital.
The Latest: Since participation in the TVL accelerator, Nanohybrids has raised $1 million in venture funding. The company is currently expanding and hiring new employees.